A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pilocarpine (Qlosi)

Cholinergic Receptor Agonist class · 9 generic manufacturers · 22 ANDAs filed at FDA.

First FDA approval2005-10-14
Generic availableYes · 9 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$32.9M in CY2024 Part D spend490K claims · 176K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.349/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.40
Across all dosage forms in distribution.
Highest NADAC
$23.25
Wide spread — brand-strength NDCs still in market.
Plans with PA
3 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Pilocarpine used for?

Pilocarpine is a Cholinergic Receptor Agonist medication tracked in Medicare Part D.

Is there a generic for Pilocarpine?

Yes. 22 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Pilocarpine?

Across 329 Part D plans, Pilocarpine averages $2.40/unit (NADAC). Lowest available: $0.349/unit. Highest in distribution: $23.25/unit.

Is Pilocarpine on the FDA shortage list?

Pilocarpine has been discontinued by its manufacturer(s).

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Cholinergic Receptor Agonist1 alternative in D1
01
Cevimeline
Brand: CEVIMELINE
$0.698Lowest NADAC
8Generic mfrs
$30.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.